Pembrolizumab: given beside what is tested

1,547 studies: usual care or a partner of the new treatment. Page 16 of 16. Open to participants first (520), then studies with results posted, then the rest; newest registration first within each.

Pembrolizumab With Nab-Paclitaxel in Non-Small Cell Lung CancerCompletedNCT02733250Phase 1/2 Report a problem
A Phase 1b Study of Demcizumab Plus Pembrolizumab in Locally Advanced or Metastatic Solid TumorsCompletedNCT02722954Phase 1 Report a problem
Dose Escalation and Cohort Expansion of Safety and Tolerability Study of Intratumoral rAd.CD40L (ISF35) in Combination of Systemic Pembrolizumab in Patients With Refractory Metastatic MelanomaWithdrawnNCT02719015Phase 1/2 Report a problem
Multicohort Phase II Trial of sEphB4-HSA+Pembrolizumab in Solid TumorsActive, not recruitingNCT02717156Phase 2 Report a problem
Early FDG PET in MelanomaTerminatedNCT02716077Not applicable Report a problem
Efficacy Study of Pembrolizumab With Entinostat to Treat Metastatic Melanoma of the EyeCompletedNCT02697630Phase 2 Report a problem
Clinical Study of CMP-001 in Combination With Pembrolizumab or as a MonotherapyCompletedNCT02680184Phase 1 Report a problem
Phase 1 Study of IMP321 (Eftilagimod Alpha) Adjuvant to Anti-PD-1 Therapy in Unresectable or Metastatic MelanomaCompletedNCT02676869Phase 1 Report a problem
CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)Status unknownNCT02675946Phase 1 Report a problem
Study of the Combination of AFM13 and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin LymphomaCompletedNCT02665650Phase 1 Report a problem
A Study of Anti-PD-1 (Pembrolizumab) Therapy in Metastatic Melanoma (ADAPTeM)WithdrawnNCT02663258Phase 2 Report a problem
A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor PatientsWithdrawnNCT02661100Phase 1/2 Report a problem
Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid TumorsCompletedNCT02646748Phase 1 Report a problem
Study of the Effects of Pembrolizumab in Patients With Advanced Solid TumorsActive, not recruitingNCT02644369Phase 2 Report a problem
Phase I Dose Escalation Study for VIP152 in Patients With Advanced CancerCompletedNCT02635672Phase 1 Report a problem
Phase 1 Open-label Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or NivolumabCompletedNCT02628574Phase 1 Report a problem
Study Comparing Pembrolizumab With Dual MAPK Pathway Inhibition Plus Pembrolizumab in Melanoma PatientsStatus unknownNCT02625337Phase 2 Report a problem
Study of Pembrolizumab With REOLYSIN® and Chemotherapy in Patients With Advanced Pancreatic AdenocarcinomaCompletedNCT02620423Phase 1 Report a problem
Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid TumorsActive, not recruitingNCT02608385Phase 1 Report a problem
Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal CancerActive, not recruitingNCT02600949Phase 1 Report a problem
MRI and PET to Assess Pembrolizumab ResponseTerminatedNCT02591654Early Phase 1 Report a problem
GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer PatientsCompletedNCT02575404Phase 1 Report a problem
Pilot Study of Vigil™ + Pembrolizumab for Advanced MelanomaCompletedNCT02574533Phase 1 Report a problem
Intratumoral CAVATAK (CVA21) and Pembrolizumab in Patients With Advanced Melanoma (VLA-011 CAPRA)CompletedNCT02565992Phase 1 Report a problem
PV-10 in Combination With Pembrolizumab for Treatment of Metastatic MelanomaActive, not recruitingNCT02557321Phase 1/2 Report a problem
Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced CancerCompletedNCT02546531Phase 1 Report a problem
A Study to Evaluate the Safety and Tolerability of ETC-1922159 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid TumoursActive, not recruitingNCT02521844Phase 1 Report a problem
A Study of Enhancing Response to MK-3475 in Advanced Colorectal CancerCompletedNCT02512172Phase 1 Report a problem
Pembrolizumab After SBRT Versus Pembrolizumab Alone in Advanced NSCLCCompletedNCT02492568Phase 2 Report a problem
A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced CancerCompletedNCT02483247Phase 1 Report a problem
A Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced CancersCompletedNCT02467361Phase 1 Report a problem
Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior TherapyActive, not recruitingNCT02432963Phase 1 Report a problem
Phase I Clinical Trial of Cryoimmunotherapy Against Prostate CancerCompletedNCT02423928Phase 1 Report a problem
In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol®CompletedNCT02423863Phase 2 Report a problem
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced MalignanciesTerminatedNCT02419495Phase 1 Report a problem
Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen MesothelinActive, not recruitingNCT02414269Phase 1/2 Report a problem
Safety Study of SEA-CD40 in Cancer PatientsTerminatedNCT02376699Phase 1 Report a problem
Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001)TerminatedNCT02346955Phase 1 Report a problem
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBMActive, not recruitingNCT02287428Phase 1 Report a problem
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)Active, not recruitingNCT02194738Not applicable Report a problem
Phase 1 Study of Intradermal LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1CompletedNCT02122861Phase 1 Report a problem
CVA21 and Pembrolizumab in NSCLC & Bladder Cancer (VLA-009 STORM/ KEYNOTE-200)CompletedNCT02043665Phase 1 Report a problem
A Study of DKN-01 in Combination With Paclitaxel or PembrolizumabCompletedNCT02013154Phase 1 Report a problem
LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or PembrolizumabCompletedNCT01986426Phase 1 Report a problem
3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAINActive, not recruitingNCT01822652Phase 1 Report a problem
Aldesleukin Imaging in Viewing Tumor Growth in Patients With Stage IV Melanoma Receiving Ipilimumab or Pembrolizumab TherapyCompletedNCT01789827Early Phase 1 Report a problem
Phase 1b Trial of Dinaciclib With Pembrolizumab for Advanced Breast CancerCompletedNCT01676753Phase 1 Report a problem

← Pembrolizumab